- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01749072
Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients
A Phase Ⅱ Randomized Clinical Trial Comparing Vinorelbine-ifosfamide With Gefitinib as Third-line Treatment in Advanced EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Ifosfamide is a first generation cytotoxic drug to treat NSCLC. Phase Ⅱ studies demonstrated that single-agent ifosfamide administrated by various schedules produces response rates of 15-29%, with media survival times of 5-7 months. Ifosfamide has also been used in various combination regimens to treat NSCLC, including platinum based and non-platinum regimens. But in refractory NSCLC patients platinum and some third generation cytotoxic drugs have been used before. So in this study, ifosfamide is combined with vinorelbine. In previous study, Masters reported the objective response rate was 40% and the median survival duration was 50 weeks, with a 1-year survival rate of 48% with vinorelbine-ifosfamide regimen [Vinorelbine 15 mg/m2 on days 1-3, and ifosfamide 2.0g/m2 on days 1-3 with granulocyte-colony stimulating factor (G-CSF) support]. The dose limiting toxicity (DLT) of this regimen is myelosuppression. In our experience, the regimen of vinorelbine 25mg/m2 d1, d8 and ifosfamide 1.25g/m2 d1-d3 with Mesna uroprotection is safe in Chinese population and the objective response rate is about 7% (data not published).
Gefitinib is the first small molecule inhibitor that has directed activity towards EGFR and has shown appreciable response rates in phase Ⅱ trials of patients with previously treated advanced NSCLC. In the posterior analysis of Iressa Dose Evaluation in Advanced Lung Cancer (IDEAL) and IRESSA Survival Evaluation in Lung Cancer (ISEL) trials, the response rate with gefitinib ranges from 2.6% to 10% in wild-type EGFR gene NSCLC patients.
Studietype
Registrering (Forventet)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Mengzhao Wang, MD
- Telefonnummer: +86 010-69155039
- E-post: mengzhaowang@sina.com
Studer Kontakt Backup
- Navn: Jing Zhao, MD
- Telefonnummer: +86 010-69158206
- E-post: pumchzj@sina.com
Studiesteder
-
-
Beijing
-
Beijing, Beijing, Kina, 100730
- Rekruttering
- Department of Respiratory Medicine, Peking Union Medical College Hospital
-
Ta kontakt med:
- Mengzhao Wang, MD
- Telefonnummer: +86 010-69155039
- E-post: mengzhaowang@sina.com
-
Ta kontakt med:
- Jing Zhao, MD
- Telefonnummer: +86 010-69158206
- E-post: pumchzj@sina.com
-
Underetterforsker:
- Wei Zhong, MD
-
Underetterforsker:
- Jinmei Luo, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- age range:18-70 years old
- life expectancy more than 12 weeks
- histologically or cytologically confirmed inoperable NSCLC (stage ⅢB/Ⅳ)
- ineligible for curative radiotherapy
- no prior radiotherapy for the target lesions
- Eastern Cooperative Oncology Group (ECOG) performance score of 0-2;
- prior treatments include first-line platinum doublet chemotherapy i.e. PC or GP and second-line chemotherapy with docetaxel or pemetrexed;
- No EGFR gene mutation detected by Scorpions-ARMS;
- at least one bidimensionally measurable or radiographically assessable lesion;
- adequate bone marrow reserve;
- adequate hepatic and renal function;
Exclusion Criteria:
- prior treatments including any of the following drugs:gefitinib,vinorelbine and ifosfamide;
- additional malignancies;
- uncontrolled systemic disease;
- any evidence of clinically active interstitial lung disease;
- newly diagnosed central nervous system (CNS) metastasis and not treated by radiotherapy or surgery;
- pregnancy or breast feeding phase;
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Annen: Gefitinib
Gefitinib group Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
|
Gefitinib 250mg once per day until the progression disease or intolerant side effects
Andre navn:
|
Annen: Vinorelbine-Ifosfamide
VI group Vinorelbine 25mg/m2 d1,d8;Ifosfamide 1.25g/m2 d1-d3(Usually Ifosfamide 2g d1-d3 with Mesna 400mg 0,4,8hours after Ifosfamide administration for 3 days);every 3 weeks;at least for 2-6 cycles depending on the progression disease or the patient's physical condition
|
Vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m1 d1-d3 (Usually 2g d1-d3); Mesna 400mg 0,4,8 hours after Ifosfamide administration for uroprotection d1-d3;
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Progression free survival
Tidsramme: up to 52 weeks (about one year)
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.
|
up to 52 weeks (about one year)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Total overlevelse
Tidsramme: Opptil 100 uker
|
Fra dato for randomisering til dato for død uansett årsak, vurdert opp til 100 uker.
|
Opptil 100 uker
|
objective response rate
Tidsramme: up to 9 weeks
|
The objective response rate includes the complete remission and partial remission rate.
|
up to 9 weeks
|
the score of functional assessment of cancer treatment-lung (FACT-L)
Tidsramme: Up to 100 weeks
|
FACL-L is assessed at different time points.(Date of randomization, 1 week after chemotherapy/EGFR-TKI, every cycle of chemotherapy/EGFR-TKI, every month of EGFR-TKI treatment/observation, up to 100 weeks)
|
Up to 100 weeks
|
Number of participants with adverse events
Tidsramme: Up to six months
|
The adverse events are assessed by National Cancer Institute-Common Toxicity Criteria (Version 3.0) (NCI-CTC).
|
Up to six months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Mengzhao Wang, MD, Department of Respiratory Medicine, Peking Unoin Medical College Hospital
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005 Nov 1;23(31):8081-92. doi: 10.1200/JCO.2005.02.7078. Epub 2005 Oct 3.
- Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006 Nov 1;24(31):5034-42. doi: 10.1200/JCO.2006.06.3958.
- Thatcher N, Anderson H, Smith DB, Steward WP, Webb K, Hilton A, Rahman A. Ifosfamide by bolus as treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 1986;18 Suppl 2:S30-3. doi: 10.1007/BF00647448.
- Holoye PY, Glisson BS, Lee JS, Dhingra HM, Murphy WK, Umsawasdi T, Levy JK, Jeffries D, Raber MN, Hong WK. Ifosfamide with mesna uroprotection in the management of lung cancer. Am J Clin Oncol. 1990 Apr;13(2):148-55. doi: 10.1097/00000421-199004000-00012.
- Masters GA, Hoffman PC, Hsieh A, Drinkard LC, Mick R, Samuels BL, Guaspari A, Golomb HM, Vokes EE. Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer. J Clin Oncol. 1997 Mar;15(3):884-92. doi: 10.1200/JCO.1997.15.3.884.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i luftveiene
- Neoplasmer
- Lungesykdommer
- Neoplasmer etter nettsted
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Lungeneoplasmer
- Karsinom, ikke-småcellet lunge
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Antineoplastiske midler, Alkylering
- Alkyleringsmidler
- Antineoplastiske midler, fytogene
- Proteinkinasehemmere
- Ifosfamid
- Gefitinib
- Vinorelbin
Andre studie-ID-numre
- PUMCH-S464
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Ikke-småcellet lungekreft
-
AHS Cancer Control AlbertaCross Cancer InstituteFullførtOmfattende Stage Small Cel Lung CancerCanada
-
Memorial Sloan Kettering Cancer CenterAktiv, ikke rekrutterendeB-celle lymfom | B-celle non-hodgkin lymfom | B Cell ALLForente stater
-
University of WashingtonNational Cancer Institute (NCI); National Comprehensive Cancer NetworkAvsluttetTilbakevendende mantelcellelymfom | Refraktært mantelcellelymfom | Ann Arbor Stage I Mantelcellelymfom | Ann Arbor Stage II mantelcellelymfom | Ann Arbor Stage III Mantle Cell Lymfom | Ann Arbor Stage IV Mantle Cell LymfomForente stater
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentTilbakefallende / Refractory Mantle Cell Lymfom (MCL)Kina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMantelcellelymfom | Blastoid Variant Mantle Cell Lymfom | Pleomorf variant av mantelcellelymfomForente stater
-
BeiGeneRekrutteringMantelcellelymfom | Residiverende mantelcellelymfom | Refractory Mantle Cell Lymfom (MCL)Forente stater, Kina, Israel, Belgia, Polen, Spania, Tyrkia, Brasil, Italia, Canada, Storbritannia, Frankrike, Tyskland, Argentina, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RekrutteringMantelcellelymfom | Blastoid Variant Mantle Cell Lymfom | Pleomorf variant av mantelcellelymfomForente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnn Arbor stadium I grad 1 follikulært lymfom | Ann Arbor stadium I grad 2 follikulært lymfom | Ann Arbor stadium II grad 1 follikulært lymfom | Ann Arbor stadium II grad 2 follikulært lymfom | Ann Arbor Stage IV B-celle non-Hodgkin lymfom | Ann Arbor Stage I B-celle non-Hodgkin lymfom | Ann Arbor... og andre forholdForente stater
-
Xiangyang No.1 People's HospitalQingdao Haier Biotechnology Co.,Ltd.Har ikke rekruttert ennåB-celle lymfom refraktært | B-celle lymfom Tilbakevendende | NK CellKina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)FullførtAnn Arbor stadium III grad 1 follikulært lymfom | Ann Arbor stadium III grad 2 follikulært lymfom | Ann Arbor Stage III Indolent voksen non-Hodgkin lymfom | Ann Arbor Stage IV Grad 1 Follikulært lymfom | Ann Arbor Stage IV Grad 2 Follikulært lymfom | Ann Arbor Stage IV Indolent voksen non-Hodgkin... og andre forholdForente stater
Kliniske studier på Gefitinib group
-
Shengjing HospitalRekruttering
-
Sun Yat-sen UniversityUkjent
-
Boston Medical CenterNational Institute of Mental Health (NIMH)FullførtPosttraumatisk stresslidelseForente stater
-
Hui-Hsun ChiangFullførtUtdanningsproblemer | Sykepleie | Vold på arbeidsplassenTaiwan
-
Ayşegül İşler DalgıçHorizonHar ikke rekruttert ennåStress, følelsesmessig | Helserisikoatferd | Helserelatert atferd | Sunn livsstil | Mangel på fysisk aktivitet | Sunn ernæring | Indeks for sunt kosthold | Ikke-smittsomme sykdommerTyrkia
-
Al-Azhar UniversityFullførtKlasse II feilslutningEgypt
-
RenJi HospitalHar ikke rekruttert ennåVæskerespons | Slagvolumvariasjon | SVV-FloTrac | Thorax elektrisk bioimpedansKina
-
RenJi HospitalHar ikke rekruttert ennåVæskerespons | Slagvolumvariasjon | SVV-FloTrac | Thorax elektrisk bioimpedansKina
-
AdventHealthAdventist UniversityFullførtSvimmelhetForente stater
-
IR Technology, LLCFullførtOvervekt | Kroppsvekt | Cellulitt | Fettbrenning | Magefett | FettvevsatrofiForente stater